Cost of weight-loss drug Mounjaro could rise significantly

Eli Lilly is substantially raising the private list price of its Mounjaro weight-loss drug in the UK by up to 170%, increasing the highest dose from £122 to £330 monthly. This hike, which spares NHS patients but impacts an estimated 90% of private UK users, is justified by Eli Lilly as an alignment with European pricing to ensure "fair global contributions to the cost of innovation," following an initial launch price "significantly below" regional averages. The move occurs amid ongoing global scrutiny of pharmaceutical pricing and could reshape the burgeoning UK market for weight-loss treatments, potentially benefiting competitors like Novo Nordisk's Wegovy.

Analysis

Eli Lilly (LLY) is strategically repositioning its Mounjaro weight-loss drug in the UK private market with a substantial list price increase of up to 170%, elevating the monthly cost of the highest dose from £122 to £330. This decision, while not impacting the heavily discounted NHS price, directly affects the vast majority of users, as an estimated nine in ten purchase these drugs privately. LLY justifies the hike as an alignment with higher European prices to ensure a "fair global contribution to the cost of innovation," correcting an initial UK launch price that was "significantly below" the regional average. This move is occurring amid heightened global scrutiny on pharmaceutical costs, including political pressure in the US. The immediate consequence is a potential erosion of Mounjaro's market share, as the negative sentiment and criticism from pharmacy associations suggest significant price sensitivity. This presents a considerable competitive opportunity for rivals like Novo Nordisk (NVO), whose Wegovy drug may now appear more attractive, especially as industry experts emphasize that affordability is critical for the continued growth of the UK's burgeoning weight-loss drug market.

Key Decisions for Investors

• Investors in Eli Lilly should closely monitor UK sales volume and prescription data for Mounjaro to assess whether the higher revenue per unit successfully offsets the risk of customer attrition to more affordable alternatives.
• The price hike on Mounjaro creates a potential catalyst for Novo Nordisk; its relative affordability could accelerate Wegovy's market share gains in the UK's private-pay segment.
• This event highlights the significant pricing power risk within the rapidly expanding weight-loss drug market, and investors should factor in potential consumer backlash and regulatory scrutiny as key variables in their valuation models for companies in this space.